Fig. 2From: Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticlesCharacterization of PLGA NPs: Fluorescein Diacetate (FDA) PLGA NPs were used as a model system to investigate the size and release profile of the NP platform described (a, b). In vitro cargo release of the NPs was evaluated in PBS at pHÂ 7.4. FDA was steadily released over the course of 120Â h. The percent of FDA released at 24, 48, 72, and 96Â h was 24%, 37%, 50%, 59%, and 70% respectively (b)Back to article page